Your browser doesn't support javascript.
loading
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Daines, Cori L; Tullis, Elizabeth; Costa, Stefano; Linnemann, Rachel W; Mall, Marcus A; McKone, Edward F; Polineni, Deepika; Quon, Bradley S; Ringshausen, Felix C; Rowe, Steven M; Selvadurai, Hiran; Taylor-Cousar, Jennifer L; Withers, Nicholas J; Ahluwalia, Neil; Moskowitz, Samuel M; Prieto-Centurion, Valentin; Tan, Yaoyuan Vincent; Tian, Simon; Weinstock, Tanya; Xuan, Fengjuan; Zhang, Yaohua; Ramsey, Bonnie; Griese, Matthias.
Afiliação
  • Daines CL; University of Arizona, Banner University Medical Center, Tucson, AZ, USA cdaines@arizona.edu.
  • Tullis E; C.L. Daines and E. Tullis contributed equally to this work.
  • Costa S; St Michael's Hospital, Toronto, ON, Canada.
  • Linnemann RW; C.L. Daines and E. Tullis contributed equally to this work.
  • Mall MA; University of Messina, Messina, Italy.
  • McKone EF; Emory University, Atlanta, GA, USA.
  • Polineni D; Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Quon BS; Berlin Institute of Health, Berlin, Germany.
  • Ringshausen FC; German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany.
  • Rowe SM; St Vincent's University Hospital, Dublin, Ireland.
  • Selvadurai H; Washington University in St Louis, St Louis, MO, USA.
  • Taylor-Cousar JL; UBC and St Paul's Hospital, Vancouver, BC, Canada.
  • Withers NJ; Hannover Medical School and German Center for Lung Research (DZL), Hannover, Germany.
  • Ahluwalia N; European Reference Network Respiratory Diseases (ERN-LUNG), Frankfurt/Main, Germany.
  • Moskowitz SM; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Prieto-Centurion V; The Children's Hospital at Westmead, Westmead, Australia.
  • Tan YV; National Jewish Health, Denver, CO, USA.
  • Tian S; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Weinstock T; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Xuan F; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Zhang Y; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Ramsey B; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Griese M; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Eur Respir J ; 62(6)2023 12.
Article em En | MEDLINE | ID: mdl-37945033
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Cística Limite: Humans Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Cística Limite: Humans Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos